Plain-English translation of NCT06098300 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
High blood pressure can damage the tiny blood vessels in your eyes, making them thinner and fewer in number—a condition called capillary rarefaction. This study uses a special eye imaging technique called Optical Coherence Tomography Angiography (OCT-A) to see if starting or adjusting blood pressure medication can actually reverse this damage and restore these tiny vessels. Researchers want to understand whether your eyes can heal when your blood pressure comes under control.
Animal studies have shown that the medication used to lower blood pressure can reverse eye vessel damage, but doctors don't yet know if this works the same way in people. This trial exists to find out whether controlling your blood pressure with the medication can actually restore the tiny blood vessels in your eyes.
You likely qualify if…
You likely don't qualify if…
You will have your eyes scanned with a special imaging camera (OCT-A) that takes detailed pictures of the tiny blood vessels in your retina—this is fast and painless, similar to an eye exam. You'll start or adjust your blood pressure medication as planned by your heart doctor, and you'll be asked to measure and record your blood pressure at home regularly. The study will track how your eye blood vessels change as your blood pressure improves over time.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
Austria
Sponsor
Medical University of Vienna
Enrollment target
~30 participants
Started
September 2023
Primary completion
August 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 90 Years
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Gerhard Garhöfer, Assoc. Prof. Priv. Doz. MD
Medical University of Vienna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.